BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice
Cheung K, Lu G, Sharma R, Vincek A, Zhang R, Plotnikov A, Zhang F, Zhang Q, Ju Y, Hu Y, Zhao L, Han X, Meslamani J, Xu F, Jaganathan A, Shen T, Zhu H, Rusinova E, Zeng L, Zhou J, Yang J, Peng L, Ohlmeyer M, Walsh M, Zhang D, Xiong H, Zhou M. BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 2952-2957. PMID: 28265070, PMCID: PMC5358349, DOI: 10.1073/pnas.1615601114.Peer-Reviewed Original ResearchConceptsBET proteinsActive RNA polymerase IITh17 cell differentiationProteins regulate gene transcriptionRecruitment of P-TEFbAcetyl-lysine bindingRNA polymerase IICell differentiationInflammatory disordersMature T helper cellsNaive CD4<sup>+</sup> T cellsCD4<sup>+</sup> T cellsDifferentiation of naive CD4<sup>+</sup> T cellsBlocking Th17-cell differentiationEpigenetic drug targetsT-cell transfer-induced colitisBromodomains of BET proteinsPolymerase IITreatment of inflammatory bowel diseaseT helper cellsTranscription elongationT helper 17Housekeeping genesGene locusDifferentiation of Th17
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply